Evidence map›Paper›PMID 40980326›Full record

ReviewFrontiers in microbiology2025

Gut microbiota-derived metabolites in keloid and hypertrophic scarring.

Junjie Jin, Zhenlong Zheng

Abstract readReview
In one paragraph

Review in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Junjie JinDepartment of Dermatology, Yanbian University Hospital, Jilin, China.
Zhenlong ZhengDepartment of Dermatology, Yanbian University Hospital, Jilin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Keloids and hypertrophic scars are fibro-proliferative skin disorders that arise from aberrant wound healing and are characterized by excessive collagen deposition and chronic inflammation. Although traditionally viewed as strictly local cutaneous phenomena, growing evidence suggests that systemic influences-particularly the gut microbiota and its metabolites-may influence scar pathogenesis. The gut microbiota produces a wide range of bioactive compounds, including short-chain fatty acids (SCFAs), bile acids, and tryptophan derivatives, which are hypothesized to modulate immune responses and pro-fibrotic signaling pathways such as TGF-

Indexed as

gut microbiomeimmunomodulationmicrobiome therapiespathological scarringskin–gut axis

Identifiers

PMID40980326
PMCPMC12446331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.